81% Chance of Trend Reversal: Crinetics Pharmaceuticals (CRNX) Price Analysis and Market Overview
Crinetics Pharmaceuticals (CRNX) has recently shown an interesting price movement, as it exceeded its 50-day Moving Average on June 16, 2023. This upward price move could potentially indicate a change in the trend, possibly leading to a sell signal for investors. Analyzing historical data, A.I.dvisor found 54 similar cases, with 44 of them resulting in successful outcomes. Based on this data, the odds of success in a potential trend reversal are estimated to be around 81%.
Are you ready to embrace the future of trading? Tickeron's AI robots empower investors to make smarter decisions.
Another significant indicator to consider is CRNX's RSI (Relative Strength Index) Indicator. On May 11, 2023, the 10-day RSI Oscillator for CRNX moved out of the overbought zone. This shift could suggest a potential shift from an upward trend to a downward trend. Traders and investors might want to carefully assess their positions, considering options such as selling the stock or buying put options. Tickeron's A.I.dvisor reviewed 27 instances where the RSI Indicator moved out of the overbought zone, and in 25 of those cases, the stock moved lower in the following days. This historical analysis provides a compelling 90% probability of a downward price move.
Considering the overall market dynamics in the biotechnology industry, it's important to understand CRNX's position in terms of market capitalization. The average market capitalization in the biotechnology industry stands at 2.17B, with a range spanning from 402 to 363.53B. NONOF holds the highest valuation in this group at 363.53B, while the lowest-valued company is PNEXF at 402.
Examining price movements in the biotechnology industry, the average weekly price growth is 1%, while the average monthly price growth is 12%. Over the span of a quarter, the average price growth reaches 39%. Notable stocks in this industry include GLSH, which experienced the highest price growth at 240%, and NBCO, which suffered the biggest fall at -80%.
Furthermore, considering volume trends in the biotechnology industry, the average weekly volume growth is 243%, indicating significant market activity. On a monthly basis, the average volume growth is 203%, while over a quarter, it reaches 11%. These volume dynamics demonstrate the active nature of the industry, with traders and investors closely monitoring stock movements.
Lastly, assessing the fundamental analysis ratings of CRNX, we find valuable insights. The valuation rating stands at 50, indicating a relatively balanced valuation. The P/E Growth Rating is at 87, reflecting positive growth potential. The Price Growth Rating is at 57, suggesting moderate price growth expectations. Additionally, the SMR Rating is at 93, indicating strong sales, margin, and return characteristics. The Profit Risk Rating stands at 94, highlighting potential risks in the company's profitability. Lastly, the Seasonality Score is at 6, indicating a neutral seasonality trend.
As always, it's important to conduct thorough research, consult with financial advisors, and carefully consider your investment goals before making any decisions based on market analysis. Understanding the various indicators and ratings can provide valuable insights, but market conditions can change rapidly. Stay informed and make investment decisions that align with your risk tolerance and long-term objectives.
Momentum Indicator for CRNX turns positive, indicating new upward trend
CRNX saw its Momentum Indicator move above the 0 level on November 21, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 97 similar instances where the indicator turned positive. In of the 97 cases, the stock moved higher in the following days. The odds of a move higher are at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for CRNX just turned positive on November 25, 2025. Looking at past instances where CRNX's MACD turned positive, the stock continued to rise in of 51 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CRNX advanced for three days, in of 279 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRNX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for CRNX entered a downward trend on November 18, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CRNX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.957) is normal, around the industry mean (27.690). P/E Ratio (0.000) is within average values for comparable stocks, (51.985). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.895). Dividend Yield (0.000) settles around the average of (0.048) among similar stocks. CRNX's P/S Ratio (2500.000) is slightly higher than the industry average of (322.277).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of therapeutics for endocrine-related diseases
Industry Biotechnology
Advertisement